

IV. Remarks

The amendments to the specification are necessary to correct inadvertent errors in which the identifiers for SEQ ID NO.s 13 and 14 were reversed in a portion of the specification. As supported in the Sequence Listing, SEQ ID NO. 13 is the nucleotide sequence encoding the amino acid sequence of SEQ ID NO. 14. Written support for the new claims can be found in the original claims and throughout the specification.

Applicants have canceled claims 24 and 27. The subject matters of claims 23 and 24 are combined in the amended claim 23 while the subject matters of claims 26 and 27 are combined in the amended claim 26. Support for amended claims 22, 25 and 28 may be found in the original claim 28. Lastly, Applicants have added substitute claims 47 and 48 to present embodiments in our independent claim format. These added claims fall within the scope of Group I and support may be found on page 4, lines 17-20 of the specification and in original claim 28. Applicants respectfully submit that no prohibited new matter has been introduced by this Preliminary Amendment.


Except for issues payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a **constructive petition for extension of time** in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully submitted

Morgan, Lewis & Bockius LLP

Dated: September 3, 2002

Morgan, Lewis & Bockius LLP
Customer No. 09629
1111 Pennsylvania, N.W.
Washington, D.C. 20004
202-739-3000


Elizabeth C. Weimar
Registration No. 44,478

Marked Up Specification Paragraphs:

On page 3, lines 27- 28:

“According to an advantageous embodiment of said protein it consists of SEQ ID NO: ~~13~~
14.”

On page 4, lines 6-7:

“According to an advantageous embodiment of said coding sequence, it consists of SEQ
ID NO: ~~14~~ 13, which corresponds to SMBP cDNA.”

On page 4, lines 8-13:

“The said SEQ ID NO: ~~14~~ 13 comprises in particular the following single restriction
sites: BstU I, Hha I, HinP I, Ava I, Sma I, Xma I, BsaA I, Apa I, Ban II, Bsp120 I, EcoO 109 I,
Sca I, Xmn I, Dra I, Nsi I, PpuI 0 I, Acc65 I, Ban I, Kpn I, Bsp1407 I, Spe I, BspD I, Cla I, Hinf
I, Tfi I, Avr II, Drd I, Esp3 I, Bpm I, PflM I, Bsm I, Alu I, BceF I, Bgl II, BstY I, ApaL I, Age I,
BsrF I, Nsp I, Nsp7524 I, NspC I, as located in figures 19, 20 and 21.”

On page 10, lines 22-3:

“Figures 19, 20 and 21 illustrate the restriction map of SEQ ID NO: ~~14~~ 13 (all sites:
figure 19; unique sites only: figure 20 and figure 21).”

On page 32, lines 10-14:

“In view to obtain the instant non-adrenergic receptor including SEQ ID NO. 1 or NO. ~~13~~
14, plasmid DNA containing human clone designated 72FO5 (EMBL accession n° z28655)
(Auffray C. et al., 1995), including the corresponding coding sequence of SEQ ID NO. 5 was

obtained from Genethon, France and was used for preparing probes useful for hybridization assays.”

On page 35, lines 13-17:

“DNA sequencing data showed a continuous open reading frame (SEQ ID NO. 2 or NO. ~~14~~ 13), translation into protein sequence (SEQ ID NO: 1 or NO: ~~13~~ 14) showed several hydrophobic stretches (figure 21), suggesting that these regions are putative membrane spanning parts of the protein. The sequences corresponding to said hydrophobic stretches are highlighted (boxes) in figure 24.”

Marked Up Changes in Claims

22. (Once Amended) Substantially pure mammal non-adrenergic receptor polypeptide ~~characterized in that it contains~~ **comprising** sites such that when said sites are exposed at the surface of a cell, they are capable of binding iodocyanopindolol (ICYP) under blockade of α , β 1, β 2, β 3-AR, serotonin 5-HT_{1A} and serotonin 5-HT_{1B} receptors, said binding being saturable, reversible, able to be displaced by a β - adrenergic receptor agonist SM-11044 with stereoselectivity but not by isoproterenol, norepinephrine, epinephrine, serotonin, dopamine or BRL-37344, and not being blocked by propranolol, said polypeptide (1) having an apparent molecular weight of about 30-40 kDa when labeled with ¹²⁵I-iodocyanopindolol after photoaffinity labeling and separation by electrophoresis and an apparent molecular weight of about 60-80 kDa in Western blot, and (2) generating a fragment having the following formula DPX₁FFQHRIHX₂FSIFNX₃ by acidic cleavage, wherein X₁ represents S (SEQ ID No. 5) or X (SEQ ID No. 6), X₂ represents V (SEQ ID No 6) or W (SEQ ID No. 5) and X₃ represents S (SEQ ID No. 5) or H (SEQ ID No. 6)

23..(Once Amended) The polypeptide according to claim 22 ~~characterized in that it contains at least~~ **comprising** SEQ ID NO. 1 **or SEQ ID NO. 14**.

24. Canceled

25. (Once Amended) An isolated and purified nucleic acid sequence ~~characterized in that it encodes~~ **encoding** a mammalian receptor as claimed in claim 22.

26. (Once Amended) The isolated and purified nucleic acid sequence of claim 25, ~~characterized in that it contains at least~~ comprising SEQ ID NO. 2 **or SEQ ID NO. 13**.

27. Canceled

28. (Once Amended) The purified nucleic acid sequence according to claim 25, ~~characterized in that it~~ **which** hybridizes with **a nucleic acid comprising** SEQ ID No. 3 or SEQ ID No. 4.